Resverlogix Corp RVXCF
Trading Information
- Previous Close Price
- $0.05
- Day Range
- $0.05–0.05
- 52-Week Range
- $0.04–0.10
- Bid/Ask
- $0.04 / $0.07
- Shares Outstanding
- 344.29M
- Market Cap
- $15.92M
- Volume/Avg
- 700 / 16,938
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 17
- Website
- https://www.resverlogix.com
Valuation
Metric | RVXCF |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | RVXCF |
|---|---|
Quick Ratio | 0.03 |
Current Ratio | 0.04 |
Interest Coverage | −1.21 |
Quick Ratio
RVXCF
Profitability
Metric | RVXCF |
|---|---|
Return on Assets (Normalized) | −121.84% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
RVXCF
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|c>d%^^J | LOCK|Lkm$ | $136B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|ssr@r& | LOCK|m>#$ | $98B | |||
| Moderna Inc MRNA | LOCK|@ZTT@Kn | LOCK|fK@ | $80B | |||
| argenx SE ADR ARGX | LOCK|!@xKyb | LOCK|!S? | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|W?q@KrP | LOCK|Ry | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|gZbB&VzQ | LOCK|FQ!? | $31B | |||
| Incyte Corp INCY | LOCK|!>C>T> | LOCK|#M | $24B | |||
| BioNTech SE ADR BNTX | LOCK|$t!@&x | LOCK|zJ | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|h^lF>Q | LOCK|$hHZ% | $20B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|QhH<&lW | LOCK|%% | $16B |